Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 38 resultados

ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE ISTITUTO ORTOPEDICO RIZZOLI participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-07 The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare...
2024-08-20 - 2031-08-31 | Financiado

ORTHO-ALLO-UNION: ORTHOpaedic treatment with ALLOgenic combined ATMP in long bone fracture delayed UNION and non union... ISTITUTO ORTOPEDICO RIZZOLI participó en un HORIZON EUROPE: HORIZON-HLTH-2023-TOOL-05 Bone fracture with delay or failure to heal is a condition with huge health impact. Although only a small proportion of long bone fractures...
2023-11-28 - 2028-11-30 | Financiado

REMEDI4ALL: BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL ISTITUTO ORTOPEDICO RIZZOLI participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 REMEDI4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice coveri...
2022-05-19 - 2027-08-31 | Financiado

ERICA: European Rare dIsease research Coordination and support Action ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-SC1-BHC-2018-2020 Rare diseases are defined as diseases that affect not more than 1 person per 2000 in the European population. While individual rare diseases...
2021-01-15 - 2025-02-28 | Financiado

ISW: In Silico World Lowering barriers to ubiquitous adoption of In Silico Trials ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-SC1-DTH-2018-2020 The overall aim of the In Silico World project is to accelerate the uptake of modelling and simulation technologies for the development and...
2020-12-04 - 2024-12-31 | Financiado

VAGABOND: Validation of Actionable Genomic ABerrations in a paediatric Oncology Network for Doctorate students ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-MSCA-ITN-2020 Pre-clinical drug development for paediatric cancers is very complex, resource intensive and requiring multi-disciplinary expertise and inno...
2020-08-18 - 2024-11-30 | Financiado

PREMUROSA: Precision medicine for muscoloskeletal regeneration prosthetics and active ageing ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-MSCA-ITN-2019 Muscoloskeletal diseases are a major burden on individuals, healthcare and welfare systems. Treatment of muscolo-skeletal disorders is curre...
2019-08-09 - 2024-09-30 | Financiado

SELNET: Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Lati... ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-SC1-BHC-2018-2020 Rare cancersRare cancers are associated with poor survival, accounting for 22% of new cancer diagnoses in Europe, and 30% of cancer deaths....
2018-12-14 - 2023-12-31 | Financiado

EJP RD: European Joint Programme on Rare Diseases ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-SC1-BHC-2018-2020 As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profi...
2018-12-13 - 2024-08-31 | Financiado

ADMAIORA: ADvanced nanocomposite MAterIals fOr in situ treatment and ultRAsound mediated management of osteoar... ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-NMBP-TR-IND-2018-2020 Osteoarthritis (OA) is a major burden that affects ~ 40 million of EU citizens, with enormous direct and indirect costs for the European hea...
2018-12-12 - 2023-12-31 | Financiado

FURTHER: Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone... ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-SC1-BHC-2018-2020 "Bone metastases are a common manifestation of advanced cancer, with pain as a devastating consequence. Due to rising cancer incidence rates...
2018-12-05 - 2025-12-31 | Financiado

MCDS-Therapy: Repurposing of carbamazepine for treatment of skeletal dysplasia ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-SC1-2016-2017 Genetic skeletal diseases (GSDs) are an extremely diverse and complex group of rare genetic diseases that affect the development the skeleto...
2017-12-05 - 2024-05-31 | Financiado

ITCC-P4: ITCC Pediatric Preclinical POC Platform Sofia ref. 116064 ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant s...
2017-05-18 - 2023-12-31 | Financiado

ORTHOUNION: ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft... ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-SC1-2016-2017 Current orthopaedic treatments permit spontaneous bone regeneration to unite and heal 90% bone injuries. Non-union associates pain and disab...
2016-12-12 - 2022-06-30 | Financiado

DeTOP: Dexterous Transradial Osseointegrated Prosthesis with neural control and sensory feedback ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-ICT-2015 This project addresses the scientific, technological and clinical problem of recovery of hand function after amputation. Despite decades of...
2015-11-10 - 2021-08-31 | Financiado

ADOPT BBMRI-ERIC: implementAtion anD OPeration of the gateway for healTh into BBMRI ERIC ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-INFRADEV-2014-2015 "BBMRI-ERIC: the Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium, aims to establ...
2015-10-21 - 2019-03-31 | Financiado

CORBEL: Coordinated Research Infrastructures Building Enduring Life science services ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-INFRADEV-2014-2015 The social and economic challenges of ageing populations and chronic disease can only be met by translation of biomedical discoveries to new...
2015-07-08 - 2020-05-31 | Financiado

ADIPOA2: Clinical trial of autologous adipose derived mesenchymal stromal cells ASC in the treatment of mil... ISTITUTO ORTOPEDICO RIZZOLI participó en un H2020: H2020-PHC-2014-2015 Osteoarthritis (OA) is an incurable disease that has evaded pharmacological interference, biologic therapy or surgical intervention to preve...
2014-12-01 - 2019-12-31 | Financiado

ORTHOWATCH: Integrating outcome registers retrieval analysis programs and preclinical validation methods into a... ISTITUTO ORTOPEDICO RIZZOLI tramitó un FP7: There is increasing demand for technology to maintain the mobility of an aging worldwide population. Joint replacement is widely recognized...
Financiado

BOCAP: Bone motion Capture from video sequences ISTITUTO ORTOPEDICO RIZZOLI tramitó un FP7: The analysis of human movements, gathering quantitative information about the musculoskeletal system during the execution of a motor task, p...
Financiado